Guggenheim Sees Zontivity and Toprol XL Bolstering Growth for Aralez Pharma (ARLZ); Affirms at 'Buy'
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Guggenheim affirms Aralez Pharmaceuticals (Nasdaq: ARLZ) at Buy with a price target of $12 following a recently-updated financial model.
Analyst Louise Chen sees Aralez being EBITDA positive by 2017. The analyst commented:
We updated our financial model to include sales for Zontivity and Toprol XL, two acquired drugs that will enhance ARZL's cardiovascular (CV) drug franchise, which currently includes Yosprala and Fibricor. We believe the Street still underestimates the earnings potential of ARLZ's CV franchise, and we believe Yosprala peak sales of $200MM+ by '22 are not fully reflected in consensus expectations yet. Additionally, we think ARLZ will be a successful consolidator of assets with its strong balance sheet, experienced management team, and low tax rate. We also modestly reduced our 3Q16 Vimovo royalty estimate, which decreased our 3Q16 EPS slightly.
FY17 revenue moves from $87.2 million up to $129.6 million and EPS was adjusted from ($0.70) out to ($0.80).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agree Realty (ADC) Tops Q3 FFO by 4c
- UPDATE: Seaport Global Securities Starts Canadian Pacific Railway Limited (CP) at Buy
- Park National Corp. (PRK) Tops Q3 EPS by 38c
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesEarnings, Louise Chen, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!